January 21, 2026 12:38 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Nitin Nabin becomes BJP’s youngest president ahead of key assembly polls, PM Modi calls him ‘my boss’ | Viral video scandal rocks Karnataka Police: DGP Ramachandra Rao suspended | Jolt to ECI over SIR! SC allows BLAs at hearing, questions 'logical discrepancy'; TMC declares 'BJP's game over' | Will dal disrupt diplomacy? US lawmakers urge Trump to act on India’s 30% pulse tariff | 'Pakistan deserves Operation Sindoor 2.0', says Baloch leader over Trump’s Gaza board invitation to Islamabad | From Malda to the nation: PM Modi unveils India’s Vande Bharat sleeper | War zone Beldanga: Highway blocked, reporters attacked in migrant death protests | Can a Nobel Peace Prize be given away? Committee breaks silence after Machado hands over medal to Trump | Europe scrambles troops to Greenland as Trump’s takeover push triggers Arctic power showdown | Nobel drama: Venezuelan leader presents Peace Prize to Trump
Chinese vaccine
Image: Unsplash

Pakistan says China's Sinopharm vaccine not recommended for people aged above 60

| @indiablooms | Feb 11, 2021, at 04:56 pm

The Chinese Sinopharm vaccine for Covid-19, which started being administered in Pakistan recently, is not recommended for people aged over 60, a top official said.

Speaking to reporters in Islamabad, Special Assistant to the Prime Minister on Health Dr Faisal Sultan was quoted as saying by Dawn News that the government's expert committee while considering the preliminary analysis of Sinopharm data had recommended that the vaccine be licensed for people aged 18-60 "at this stage".

"At this stage, the [committee] did not authorise the vaccine for people older than 60," he added.

When contacted by Dawn News about which vaccine would be used for people over 60 instead of Sinopharm's, Dr Sultan said the AstraZeneca vaccine would be used.

"When our Pakistani experts looked at the data, they were reasonably satisfied with the AstraZeneca data but felt that [based] on the presently available numbers for Sinopharm, the data did not justify its usage for those aged over 60," he said.

"The Chinese have also reiterated this restriction," he added.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.